Nature Reviews Drug Discovery
@natrevdrugdiscov.nature.com
Editorial team of Nature Reviews Drug Discovery
www.nature.com/nrd
www.nature.com/nrd
FDA approves 100th small-molecule kinase inhibitor www.nature.com/articles/d41...
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
November 17, 2025 at 3:12 PM
FDA approves 100th small-molecule kinase inhibitor www.nature.com/articles/d41...
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
For readers interested in GLP-1-based therapies for diabetes, obesity and beyond, here's a recent review
rdcu.be/ePXoK
www.nature.com/articles/s41...
rdcu.be/ePXoK
www.nature.com/articles/s41...
GLP-1-based therapies for diabetes, obesity and beyond
Nature Reviews Drug Discovery - GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based...
rdcu.be
November 14, 2025 at 4:28 PM
For readers interested in GLP-1-based therapies for diabetes, obesity and beyond, here's a recent review
rdcu.be/ePXoK
www.nature.com/articles/s41...
rdcu.be/ePXoK
www.nature.com/articles/s41...
Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot nature.com/articles/d41...
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
November 14, 2025 at 4:25 PM
Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot nature.com/articles/d41...
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
Reposted by Nature Reviews Drug Discovery
New from the @hansclevers.bsky.social group Drug screening and human organoids @natrevdrugdiscov.nature.com www.nature.com/articles/s41...
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges - Nature Reviews Drug Discovery
Human organoids provide physiologically relevant, 3D models for studying disease mechanisms, drug efficacy and toxicity. This Review examines organoid generation methods, applications in preclinical d...
www.nature.com
November 12, 2025 at 12:15 PM
New from the @hansclevers.bsky.social group Drug screening and human organoids @natrevdrugdiscov.nature.com www.nature.com/articles/s41...
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges - Nature Reviews Drug Discovery
Human organoids provide physiologically relevant, 3D models for studying disease mechanisms, drug efficacy and toxicity. This Review examines organoid generation methods, applications in preclinical d...
www.nature.com
November 12, 2025 at 3:12 PM
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
This article in the November issue discusses the changing landscape of medicinal chemistry optimization based on analysis of sets of hits, leads and drug candidates, which reveals shifts in key physicochemical properties
rdcu.be/ePoB9
www.nature.com/articles/s41...
rdcu.be/ePoB9
www.nature.com/articles/s41...
The changing landscape of medicinal chemistry optimization
Nature Reviews Drug Discovery - Medicinal chemistry optimizations in the progression from hit to lead to drug candidate affect properties of small-molecule drugs such as their molecular weight and...
rdcu.be
November 11, 2025 at 3:23 PM
This article in the November issue discusses the changing landscape of medicinal chemistry optimization based on analysis of sets of hits, leads and drug candidates, which reveals shifts in key physicochemical properties
rdcu.be/ePoB9
www.nature.com/articles/s41...
rdcu.be/ePoB9
www.nature.com/articles/s41...
For readers interested in therapies that harness regulatory T cells to treat disease, here's a review on this topic rdcu.be/ePb76 www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...
Harnessing the biology of regulatory T cells to treat disease
Nature Reviews Drug Discovery - Regulatory T cells keep the immune system in check to maintain homeostasis and restrain inflammation. This Review discusses strategies to harness these cells...
rdcu.be
November 10, 2025 at 3:23 PM
For readers interested in therapies that harness regulatory T cells to treat disease, here's a review on this topic rdcu.be/ePb76 www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...
“It’s about time”: Tregs win the Nobel prize
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
“It’s about time”: Tregs win the Nobel prize
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of Treg therapies.
www.nature.com
November 10, 2025 at 3:15 PM
“It’s about time”: Tregs win the Nobel prize
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
For readers interested in bispecific antibodies as cancer therapies, here's a review
rdcu.be/eOONr
www.nature.com/articles/s41...
rdcu.be/eOONr
www.nature.com/articles/s41...
The present and future of bispecific antibodies for cancer therapy
Nature Reviews Drug Discovery - Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent...
rdcu.be
November 7, 2025 at 3:43 PM
For readers interested in bispecific antibodies as cancer therapies, here's a review
rdcu.be/eOONr
www.nature.com/articles/s41...
rdcu.be/eOONr
www.nature.com/articles/s41...
Innovative antibody therapeutic development in China compared with the USA and Europe nature.com/articles/d41...
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Innovative antibody therapeutic development in China compared with the USA and Europe
Discover the world’s best science and medicine | Nature.com
nature.com
November 7, 2025 at 3:40 PM
Innovative antibody therapeutic development in China compared with the USA and Europe nature.com/articles/d41...
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Cancer cell therapies: global clinical trial trends and emerging directions www.nature.com/articles/d41...
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
Cancer cell therapies: global clinical trial trends and emerging directions
Discover the world’s best science and medicine | Nature.com
www.nature.com
November 6, 2025 at 3:54 PM
Cancer cell therapies: global clinical trial trends and emerging directions www.nature.com/articles/d41...
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
For readers interested in the development of drugs for fibrotic diseases such as idiopathic pulmonary fibrosis, here's a review discussing the underlying biology and how to address the translational research challenges
rdcu.be/eOpGH
www.nature.com/articles/s41...
rdcu.be/eOpGH
www.nature.com/articles/s41...
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Nature Reviews Drug Discovery - Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in...
rdcu.be
November 5, 2025 at 3:39 PM
For readers interested in the development of drugs for fibrotic diseases such as idiopathic pulmonary fibrosis, here's a review discussing the underlying biology and how to address the translational research challenges
rdcu.be/eOpGH
www.nature.com/articles/s41...
rdcu.be/eOpGH
www.nature.com/articles/s41...
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis www.nature.com/articles/d41...
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
November 5, 2025 at 3:35 PM
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis www.nature.com/articles/d41...
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Induced proximity-based therapeutic modalities
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
Induced proximity-based therapeutic modalities - Nature Reviews Drug Discovery
Induced proximity modalities encompass monovalent and bifunctional agents, such as molecular glues and proteolysis-targeting chimeras, that induce an interaction between biomolecules to functionally m...
nature.com
November 4, 2025 at 4:12 PM
Induced proximity-based therapeutic modalities
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review
rdcu.be/eN4SK
www.nature.com/articles/s41...
rdcu.be/eN4SK
www.nature.com/articles/s41...
November 3, 2025 at 4:31 PM
For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review
rdcu.be/eN4SK
www.nature.com/articles/s41...
rdcu.be/eN4SK
www.nature.com/articles/s41...
Reposted by Nature Reviews Drug Discovery
Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061
October 30, 2025 at 5:30 PM
Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061
Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here www.nature.com/nrd/volumes/...
October 30, 2025 at 2:42 PM
Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here www.nature.com/nrd/volumes/...
For readers interested in new drugs for chronic obstructive pulmonary disease, here's a comprehensive review
rdcu.be/eNiYv
www.nature.com/articles/s41...
rdcu.be/eNiYv
www.nature.com/articles/s41...
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Nature Reviews Drug Discovery - Chronic obstructive pulmonary disease (COPD) is a progressive and severe respiratory disease featuring airway obstruction and recurrent exacerbations, driven by a...
rdcu.be
October 29, 2025 at 3:04 PM
For readers interested in new drugs for chronic obstructive pulmonary disease, here's a comprehensive review
rdcu.be/eNiYv
www.nature.com/articles/s41...
rdcu.be/eNiYv
www.nature.com/articles/s41...
Reposted by Nature Reviews Drug Discovery
In its second pipeline-expanding deal in the space of 24 hours, #GSK has licensed rights to a drug for chronic obstructive pulmonary disease (#COPD) from US biotech #Empirico for $85 million upfront.
pharmaphorum.com/news/gsk-str...
pharmaphorum.com/news/gsk-str...
October 28, 2025 at 12:47 PM
In its second pipeline-expanding deal in the space of 24 hours, #GSK has licensed rights to a drug for chronic obstructive pulmonary disease (#COPD) from US biotech #Empirico for $85 million upfront.
pharmaphorum.com/news/gsk-str...
pharmaphorum.com/news/gsk-str...
For readers interested in the potential to target particular protein isoforms as a way to achieve greater drug specificity, here's a review
rdcu.be/eNiHj
www.nature.com/articles/s41...
rdcu.be/eNiHj
www.nature.com/articles/s41...
Protein isoform-centric therapeutics: expanding targets and increasing specificity
Nature Reviews Drug Discovery - Multiple protein isoforms arise from most genes by alternative RNA splicing and other mechanisms, but these isoforms are often neglected in drug discovery. This...
rdcu.be
October 29, 2025 at 2:47 PM
For readers interested in the potential to target particular protein isoforms as a way to achieve greater drug specificity, here's a review
rdcu.be/eNiHj
www.nature.com/articles/s41...
rdcu.be/eNiHj
www.nature.com/articles/s41...
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety
www.nature.com/articles/s41...
rdcu.be/eM8hs
This new Perspective discusses QST models for multiple organs and provides recommendations for building and applying them
www.nature.com/articles/s41...
rdcu.be/eM8hs
This new Perspective discusses QST models for multiple organs and provides recommendations for building and applying them
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety - Nature Reviews Drug Discovery
Quantitative systems toxicology (QST) models have the potential to increase confidence in the safety assessment of drug candidates and to inform project progression decisions. This article overviews t...
www.nature.com
October 28, 2025 at 3:17 PM
Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety
www.nature.com/articles/s41...
rdcu.be/eM8hs
This new Perspective discusses QST models for multiple organs and provides recommendations for building and applying them
www.nature.com/articles/s41...
rdcu.be/eM8hs
This new Perspective discusses QST models for multiple organs and provides recommendations for building and applying them
For readers interested in lipid nanoparticles for nucleic acid delivery, here's a perspective by Cullis and Feldner on the evolution of the field
rdcu.be/eMpeO
nature.com/articles/s41...
rdcu.be/eMpeO
nature.com/articles/s41...
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Nature Reviews Drug Discovery - Lipid nanoparticle-based systems are increasingly being utilized for the delivery of nucleic acid-based vaccines and therapeutics. In this Perspective, Cullis and...
rdcu.be
October 23, 2025 at 3:09 PM
For readers interested in lipid nanoparticles for nucleic acid delivery, here's a perspective by Cullis and Feldner on the evolution of the field
rdcu.be/eMpeO
nature.com/articles/s41...
rdcu.be/eMpeO
nature.com/articles/s41...
Trends in gene therapy delivery technologies nature.com/articles/d41...
This article analyses trends in the delivery vehicles used for gene therapies in the clinical pipeline and discusses the potential characteristics of best-in-class delivery
This article analyses trends in the delivery vehicles used for gene therapies in the clinical pipeline and discusses the potential characteristics of best-in-class delivery
Trends in gene therapy delivery technologies
Discover the world’s best science and medicine | Nature.com
nature.com
October 23, 2025 at 3:08 PM
Trends in gene therapy delivery technologies nature.com/articles/d41...
This article analyses trends in the delivery vehicles used for gene therapies in the clinical pipeline and discusses the potential characteristics of best-in-class delivery
This article analyses trends in the delivery vehicles used for gene therapies in the clinical pipeline and discusses the potential characteristics of best-in-class delivery
Reposted by Nature Reviews Drug Discovery
Join researchers, biotech innovators, and pharma leaders in Boston this December for Cracking the Code: Nucleic Acid Medicines Coming of Age. Explore how advances in RNA and DNA therapeutics are shaping the next generation of medicine. go.nature.com/4nbCcaK 🧬#STEMconference
October 21, 2025 at 5:39 PM
Join researchers, biotech innovators, and pharma leaders in Boston this December for Cracking the Code: Nucleic Acid Medicines Coming of Age. Explore how advances in RNA and DNA therapeutics are shaping the next generation of medicine. go.nature.com/4nbCcaK 🧬#STEMconference
Intrinsically disordered proteins are frequently dysregulated in disease, but have traditionally been considered 'undruggable'. This Review in the October issue discusses experimental and computational approaches to conquer this barrier in drug discovery
rdcu.be/eMbXh
www.nature.com/articles/s41...
rdcu.be/eMbXh
www.nature.com/articles/s41...
Targeting protein disorder: the next hurdle in drug discovery
Nature Reviews Drug Discovery - Intrinsically disordered proteins are frequently dysregulated in many diseases, but because of their heterogeneous, highly dynamic structural states they have been...
rdcu.be
October 22, 2025 at 2:13 PM
Intrinsically disordered proteins are frequently dysregulated in disease, but have traditionally been considered 'undruggable'. This Review in the October issue discusses experimental and computational approaches to conquer this barrier in drug discovery
rdcu.be/eMbXh
www.nature.com/articles/s41...
rdcu.be/eMbXh
www.nature.com/articles/s41...